Post-Vaccination Syndrome (post-vaccination-syndrome)
1 Krumholz et al. 2023 — Post-Vaccination Syndrome: A Descriptive Analysis
Full Citation:: Krumholz HM, Wu Y, Sawano M, et al. Post-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms and Patient Experiences After COVID-19 Immunization. medRxiv. 2023. (Krumholz et al. 2023) DOI:: 10.1101/2023.11.09.23298266 PMID:: 37986769 Article Type:: Preprint (descriptive cross-sectional, Yale LISTEN study) Key Findings::
- n = 241 self-reported PVS after COVID-19 vaccination; median age 46 y; 80% female; 55% BNT162b2 / 37% mRNA-1273; median symptom onset 3 days post-vaccination
- Top symptoms: exercise intolerance 71%, excessive fatigue 69%, numbness 63%, brain fog 63%, neuropathy 63%
- Median EuroQoL VAS 50; participants reported a median of 20 interventions tried; high psychosocial distressConclusion:: Self-reported PVS carries low health status, high symptom burden, and high distress despite many treatments. Limitations:: Self-selected online cohort; no controls; preprint (not yet peer-reviewed); self-report without objective verification of vaccination or symptom attribution. ME/CFS Relevance:: F1 — the foundational descriptive phenotype of PVS; symptoms (fatigue, PEM-like exercise intolerance, brain fog, neuropathy) overlap ME/CFS. Certainty Assessment::
- *Quality:* Low (preprint, self-selected)
- *Sample:* n = 241
- *Replication:* Single study
- *Score:* 0.40 (raw; population 0.75 → discounted 0.30)2 Mundorf et al. 2024 — Clinical and Diagnostic Features of PACVS
Full Citation:: Mundorf AK, Semmler A, Heidecke H, et al. Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS). Vaccines. 2024;12(7):790. (Mundorf et al. 2024) DOI:: 10.3390/vaccines12070790 PMID:: 39066428 Article Type:: Prospective registry cohort (PACVS) Key Findings::
- n = 191 PACVS (159 F / 32 M); unbiased symptom clustering: malaise + chronic fatigue in >80% of cases
- IL-6 and IL-8 elevated in >80%; low free T3 in >80%; IgG subclass imbalance >50%; elevated serum NfL >30%
- 131/191 fit ME/CFS plus several dysautonomia syndromes; 31/191 fit noneConclusion:: PACVS is a chronic disease with a core malaise/fatigue phenotype plus overlapping peripheral-nerve, cardiovascular, and cognitive clusters; may be an ME/CFS outlier or a dysautonomia syndrome sui generis. Limitations:: Self-help-group recruitment; no pre-vaccination baseline; cross-sectional single-center. ME/CFS Relevance:: F1 — establishes the PACVS clinical phenotype and its ME/CFS overlap (131/191 fit ME/CFS). Certainty Assessment::
- *Quality:* Medium (peer-reviewed registry cohort)
- *Sample:* n = 191
- *Replication:* Single cohort (overlaps Semmler 2023)
- *Score:* 0.55 (raw; population 0.85 → discounted 0.47)3 Semmler et al. 2023 — Chronic Fatigue and Dysautonomia: Altered Blood Markers
Full Citation:: Semmler A, Mundorf AK, Kuechler AS, et al. Chronic Fatigue and Dysautonomia following COVID-19 Vaccination Is Distinguished from Normal Vaccination Response by Altered Blood Markers. Vaccines. 2023;11(11):1642. (Semmler et al. 2023) DOI:: 10.3390/vaccines11111642 PMID:: 38005974 Article Type:: Prospective cohort + healthy controls Key Findings::
- n = 191 PACVS vs 89 healthy controls, blood markers before vs 6 months after vaccination
- PACVS discriminated from normal post-vaccination state (sensitivity 90%) by increased AT1 receptor antibodies (AUC 0.824), decreased alpha-2B adrenergic antibodies (AUC 0.828), increased IL-6 (AUC 0.850)Conclusion:: PACVS is a somatic syndrome delineated and detectable by diagnostic blood markers (receptor antibodies + IL-6). Limitations:: Self-help-group recruitment; same PACVS cohort as Mundorf 2024 (overlap); case-control without independent replication. ME/CFS Relevance:: F1 — the strongest biomarker evidence distinguishing PACVS from normal vaccine response; implicates GPCR autoantibodies. Certainty Assessment::
- *Quality:* Medium (peer-reviewed)
- *Sample:* n = 280 total
- *Replication:* Single cohort
- *Score:* 0.55 (raw; population 0.85 → discounted 0.47)4 Yong et al. 2025 — Long Vax Syndrome: Manifestation, Pathophysiology, Therapies
Full Citation:: Yong SJ, Kenny TA, Halim A, et al. Post-COVID-19 Vaccination (or Long Vax) Syndrome: Putative Manifestation, Pathophysiology, and Therapeutic Options. Reviews in Medical Virology. 2025;35(5):e70070. (Yong et al. 2025) DOI:: 10.1002/rmv.70070 PMID:: 40944962 Article Type:: Narrative review Key Findings::
- PCVS manifests days–weeks post-vaccination, symptoms lasting months–years; may present as POTS, SFN, ME/CFS, or sequelae of myocarditis/VITT/ITP
- Symptomatically overlaps long COVID (fatigue, brain fog) but with more paraesthesia and less dyspnoea
- Reviews vaccine-derived spike protein + immune-response hypotheses and case-report-based therapiesConclusion:: PCVS is poorly understood; needs research on prevalence, prognosis, risk factors, and treatments. Limitations:: Narrative; evidence mostly case reports/series and observational; no primary data. ME/CFS Relevance:: F1 — the reference narrative review naming PCVS and its ME/CFS presentation. Certainty Assessment::
- *Quality:* Medium (peer-reviewed review)
- *Sample:* N/A (review)
- *Replication:* N/A
- *Score:* 0.40 (raw; population 0.75 → discounted 0.30)5 Hanc et al. 2026 — Cognitive Impairment, Depression, Fatigue in PC and PVS
Full Citation:: Hanc E, Koller K, Herold R, Erim Y, Morawa E. Cognitive impairment, depression, and fatigue in post-COVID and post-vaccination syndrome: a large-scale cross-sectional study. European Archives of Psychiatry and Clinical Neuroscience. 2026;276(1):221–234. (Hanc et al. 2026) DOI:: 10.1007/s00406-025-02144-3 PMID:: 41258118 Article Type:: Large cross-sectional study Key Findings::
- N = 793 (723 PASC + 70 PVS), mean age 46 y, 67% female; Erlangen Post-COVID Center
- Deficits most frequent in working speed 61.7%, attention 54.7%, verbal fluency 48.8%; fatigue 92.4%; depressive symptoms 64.5%
- Cognitive patterns, depression, and fatigue in PVS closely resembled PASC — shared mechanismsConclusion:: Cognitive impairment is highly prevalent in both PASC and PVS and is influenced by psychological and biological factors. Limitations:: Cross-sectional; PVS group small (n = 70); self-report symptom attribution; single-center. ME/CFS Relevance:: F1/F3 — the largest direct PVS-vs-PASC neuropsychological comparison. Certainty Assessment::
- *Quality:* Medium–high (peer-reviewed, large N)
- *Sample:* N = 793
- *Replication:* Single center
- *Score:* 0.55 (raw; population 0.85 → discounted 0.47)6 Bhattacharjee et al. 2025 — Immunological and Antigenic Signatures of PVS
Full Citation:: Bhattacharjee B, Lu P, Monteiro VS, et al. Immunological and Antigenic Signatures Associated with Chronic Illnesses after COVID-19 Vaccination. medRxiv. 2025. (Bhattacharjee et al. 2025) DOI:: 10.1101/2025.02.18.25322379 Article Type:: Preprint (cross-sectional mechanistic) Key Findings::
- n = 42 PVS vs 22 healthy vaccinated controls (Yale LISTEN, Iwasaki/Krumholz)
- Reports longer-lasting spike protein detection, reactivated EBV, and distinct immune signatures in PVS vs controlsConclusion:: PVS is associated with measurable antigenic and immunological alterations (spike persistence, EBV reactivation). Limitations:: Preprint (not yet peer-reviewed at search time); small n; cross-sectional; overlaps Yale LISTEN PVS cohort. ME/CFS Relevance:: F3 — mechanistic link between PVS and the spike-persistence / EBV-reactivation pathways shared with Long COVID. Certainty Assessment::
- *Quality:* Low (preprint)
- *Sample:* n = 64
- *Replication:* Single study
- *Score:* 0.40 (raw; population 0.85 → discounted 0.34)7 Arlt et al. 2024 — Autoreactive IgG Against Peripheral Nerve in PCVS
Full Citation:: Arlt FA, Breuer A, Trampenau E, et al. High serum prevalence of autoreactive IgG antibodies against peripheral nerve structures in patients with neurological post-COVID-19 vaccination syndrome. Frontiers in Immunology. 2024;15:1404800. (Arlt et al. 2024) DOI:: 10.3389/fimmu.2024.1404800 PMID:: 39156891 Article Type:: Case-control Key Findings::
- n = 50 PCVS (peripheral neurological symptoms) vs 35 vaccinated controls
- IgG autoantibodies against peripheral-nerve structures more frequent in PCVS (18% vs 3%, p = 0.04); bound paranodes, axons, Schmidt-Lanterman incisures, Schwann nuclei
- Target epitopes: neurofilament subunits and DFS-70; anti-ganglioside antibodies absentConclusion:: Autoantibodies against nervous system tissue may be relevant in PCVS; neurofilament and DFS-70 autoantibodies have biomarker potential. Limitations:: Small n; autoantibody pathogenicity not demonstrated; no longitudinal follow-up. ME/CFS Relevance:: F3 — autoantibody (anti-nerve) evidence tying PVS to the immune-mediated mechanism shared with ME/CFS/Long COVID. Certainty Assessment::
- *Quality:* Medium (peer-reviewed case-control)
- *Sample:* n = 85
- *Replication:* Single study
- *Score:* 0.50 (raw; population 0.85 → discounted 0.43)8 Purpura et al. 2026 — Long COVID vs PACVS: Phenotypes, Severity, Biomarkers
Full Citation:: Purpura L, Heisler T, Palmer S, et al. Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers. Clinical Infectious Diseases. 2026;82(5):e923–e931. (Purpura et al. 2026) DOI:: 10.1093/cid/ciaf624 PMID:: 41510565 Article Type:: Cross-sectional cohort Key Findings::
- n = 181 from a Columbia PASC clinic (PASC-MECFS, PASC-LC, PACVS); fatigue most common (total 88.95%; MECFS 100%; PACVS 92.86%)
- PACVS higher atypical complaints: peripheral neuropathy 17.9%, tinnitus 7.1%, rash 10.7% (p < 0.01)
- PACVS higher anticardiolipin IgM (42.9% vs 11.6%, p = 0.02) and anti-U1-RNP (21.4% vs 2.3%, p = 0.04); functional impairment comparable between MECFS and PACVSConclusion:: PASC and PACVS share symptoms but PACVS shows distinct autoantibody elevations — autoimmune involvement. Limitations:: Cross-sectional; PACVS group modest size; single-center; self-report. ME/CFS Relevance:: F3 — direct head-to-head LC-vs-PACVS biomarker comparison showing autoantibody signature. Certainty Assessment::
- *Quality:* Medium–high (peer-reviewed)
- *Sample:* n = 181
- *Replication:* Single center
- *Score:* 0.55 (raw; population 0.85 → discounted 0.47)9 Donadio et al. 2025 — Small Fiber Neuropathy: Infection vs Vaccination
Full Citation:: Donadio V, Incensi A, Furia A, et al. Small fiber neuropathy associated with COVID-19 infection and vaccination: A prospective case-control study. European Journal of Neurology. 2025;32(1):e16538. (Donadio et al. 2025) DOI:: 10.1111/ene.16538 PMID:: 39526678 Article Type:: Prospective case-control Key Findings::
- n = 33 post-COVID + 33 post-mRNA-vaccination + 33 pre-2019 controls (skin biopsy)
- Somatic small-nerve-fiber density reduced in both vs controls; SFN more frequent post-infection (94%) than post-vaccination (79%)
- Autoimmune abnormalities frequent in both but NOT correlated with SFN; skin autonomic innervation sparedConclusion:: Somatic SFN is common after both infection and vaccination, with infection the stronger driver; SFN is not explained by autoimmune markers. Limitations:: Modest n; no causal attribution; single center. ME/CFS Relevance:: F3/F4 — SFN (a proposed ME/CFS/POTS substrate) occurs after both triggers, more so after infection. Certainty Assessment::
- *Quality:* Medium (peer-reviewed)
- *Sample:* n = 99
- *Replication:* Single study
- *Score:* 0.55 (raw; population 0.85 → discounted 0.47)10 Leys et al. 2025 — POTS After COVID-19 Infection or Vaccination
Full Citation:: Leys F, Verginer M, Kirchler E, et al. Postural orthostatic tachycardia syndrome is the most frequent cardiovascular autonomic disorder following COVID-19 infection or vaccination. Journal of Neurology. 2025;272(12):783. (Leys et al. 2025) DOI:: 10.1007/s00415-025-13518-x PMID:: 41275041 Article Type:: Retrospective cohort Key Findings::
- Innsbruck Dysautonomia Center (03/2020–03/2023): post-infection n = 75 (29% POTS); post-vaccination n = 26 (42% POTS)
- In 49/101 (49%) new referrals, workup excluded any cardiovascular autonomic disorder
- Multimodal treatment improved symptoms in 26/42 (62%) with follow-upConclusion:: POTS is the most frequent cardiovascular autonomic disorder after either trigger; a specialist workup is pivotal and treatment is often helpful. Limitations:: Retrospective; referral bias; small vaccinated subgroup. ME/CFS Relevance:: F3/F4 — quantifies POTS (a ME/CFS-overlap dysautonomia) after both infection and vaccination. Certainty Assessment::
- *Quality:* Medium (peer-reviewed)
- *Sample:* n = 101
- *Replication:* Single center
- *Score:* 0.55 (raw; population 0.85 → discounted 0.47)11 Feiring et al. 2017 — HPV Vaccine and CFS/ME Risk (Norway)
Full Citation:: Feiring B, Laake I, Bakken IJ, et al. HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway. Vaccine. 2017;35(33):4203–4212. (Feiring et al. 2017) DOI:: 10.1016/j.vaccine.2017.06.031 PMID:: 28648542 Article Type:: Nationwide register-based cohort Key Findings::
- 176,453 girls born 1997–2002 (824,133 age 10–17); linked national registries
- HPV vaccination NOT associated with CFS/ME: HR 0.86 (0.69–1.08) full follow-up; 0.96 (0.64–1.43) first two years
- Prior hospital contacts strongly predicted CFS/ME (HR 5.23 for ≥7 contacts)Conclusion:: No increased CFS/ME risk following HPV vaccination in the first six birth cohorts offered it. Limitations:: Observational; CFS/ME registry codes (no research criteria); residual confounding. ME/CFS Relevance:: F2 null — a large national negative result against vaccine causation of ME/CFS. Certainty Assessment::
- *Quality:* High (nationwide register)
- *Sample:* n = 176,453
- *Replication:* Independent of Magnus 2015 (same NIPH group)
- *Score:* 0.70 (raw; population 0.75 → discounted 0.53)12 Hviid et al. 2020 — HPV Vaccine and Autonomic Dysfunction Syndromes (Denmark)
Full Citation:: Hviid A, Thorsen NM, Valentiner-Branth P, Frisch M, Mølbak K. Association between quadrivalent human papillomavirus vaccination and selected syndromes with autonomic dysfunction in Danish females: population based, self-controlled, case series analysis. BMJ. 2020;370:m2930. (Hviid et al. 2020) DOI:: 10.1136/bmj.m2930 PMID:: 32878745 Article Type:: Population-based self-controlled case series Key Findings::
- 869 autonomic-dysfunction cases (136 CFS, 535 CRPS, 198 POTS) from 1,375,737 Danish females
- HPV vaccination did NOT increase composite outcome in 365-day risk period (RR 0.99, 0.74–1.32), nor CFS (0.38, 0.13–1.09)
- Up to 32% increased risk not formally excludedConclusion:: No causal association between HPV vaccination and CFS, CRPS, or POTS. Limitations:: Self-controlled design (no external comparison); low syndrome counts; up to 32% risk not excludable. ME/CFS Relevance:: F2 null — a high-quality Danish negative against HPV-vaccine causation of CFS/dysautonomia. Certainty Assessment::
- *Quality:* High (national register, SCCS)
- *Sample:* n = 1,375,737
- *Replication:* Independent
- *Score:* 0.70 (raw; population 0.75 → discounted 0.53)13 Jensen et al. 2025 — Post-Acute Non-Specific Symptoms After COVID-19 Vaccination
Full Citation:: Jensen CB, Hansen KT, Bech BH, et al. Post-acute non-specific symptoms following COVID-19 vaccination: a Danish population-based study. International Journal of Epidemiology. 2025;54(5):dyaf173. (Jensen et al. 2025) DOI:: 10.1093/ije/dyaf173 PMID:: 41070980 Article Type:: Longitudinal population cohort (BiCoVac) Key Findings::
- 132,776 observations from 61,316 unconcerned / 25,272 sceptical / 5,064 concerned individuals
- Among unconcerned, vaccinated had LOWER odds of most symptoms >4 weeks post-vaccination (muscular pain OR 0.56, 0.47–0.68)
- Only vaccine-concerned individuals reported higher odds (muscular pain OR 1.23, 0.91–1.67) — reporting bias / noceboConclusion:: For most people there is no evidence of post-acute symptoms after COVID-19 vaccination; symptom reporting is concentrated in vaccine-concerned individuals. Limitations:: Self-report symptoms; observational; no clinical verification of symptoms. ME/CFS Relevance:: F2 null/nocebo — the strongest direct population-level null against post-vaccination symptom causation. Certainty Assessment::
- *Quality:* High (large longitudinal cohort)
- *Sample:* 132,776 observations
- *Replication:* Independent
- *Score:* 0.65 (raw; population 0.75 → discounted 0.49)14 Kwan et al. 2022 — POTS Risk After Vaccination vs Infection
Full Citation:: Kwan AC, Ebinger JE, Wei J, et al. Apparent Risks of Postural Orthostatic Tachycardia Syndrome Diagnoses After COVID-19 Vaccination and SARS-CoV-2 Infection. Nature Cardiovascular Research. 2022;1(12):1187–1194. (Kwan et al. 2022) DOI:: 10.1038/s44161-022-00177-8 PMID:: 37303827 Article Type:: Sequence-symmetry analysis Key Findings::
- n = 284,592 vaccinated (Cedars-Sinai); POTS odds higher 90 days after vaccine than 90 days before
- Post-vaccination POTS odds lower than post-infection odds (post-infection ~5× higher)Conclusion:: A possible association between COVID-19 vaccination and POTS exists but is small relative to post-infection POTS. Limitations:: Observational sequence-symmetry; diagnostic code reliance; no mechanistic data. ME/CFS Relevance:: F2 relative null — vaccine-POTS is real but far lower than infection-POTS. Certainty Assessment::
- *Quality:* Medium–high (peer-reviewed)
- *Sample:* n = 284,592
- *Replication:* Single cohort (re-used in Bushi 2024 SR)
- *Score:* 0.65 (raw; population 0.75 → discounted 0.49)15 Yang & Wang 2026 — Post-Vaccination Syndromes: Evidence and Roadmap
Full Citation:: Yang D, Wang G. Post-Vaccination Syndromes: The Evidence and a Roadmap for Rigorous Research. Reviews in Medical Virology. 2026;36(1):e70100. (Yang and Wang 2026) DOI:: 10.1002/rmv.70100 PMID:: 41467340 Article Type:: Letter / critique Key Findings::
- Critical appraisal of Yong 2025: methodological limitations, ascertainment bias, conflation of correlation with causation
- Argues background prevalence of POTS/chronic fatigue is non-negligible; mechanisms speculative without human validation; proposed therapies empiric and untested
- Calls for prospective controlled cohorts, deep phenotyping, and standardised criteria before RCTsConclusion:: The PVS evidence base is premature; disciplined research is needed before clinical guidance. Limitations:: Letter (not primary evidence); no new data. ME/CFS Relevance:: F2 critique — the formal counterpoint to the PCVS narrative; frames the causal-inference weakness. Certainty Assessment::
- *Quality:* Low (letter)
- *Sample:* N/A
- *Replication:* N/A
- *Score:* 0.35 (raw; population 0.75 → discounted 0.26)16 Patone et al. 2022 — Myocarditis/Pericarditis Risk After Vaccination vs Infection
Full Citation:: Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nature Medicine. 2022;28(2):410–422. (Patone et al. 2022) DOI:: 10.1038/s41591-021-01630-0 PMID:: 34907393 Article Type:: Self-controlled case series (England) Key Findings::
- ~38M vaccinated (ChAdOx1 20.6M; BNT162b2 17.0M; mRNA-1273 1.0M) + 3.0M SARS-CoV-2 positive
- Myocarditis risk increased after first/second mRNA doses (extra 1–10 events per million in 28 days), confined to age under 40
- SARS-CoV-2 infection carried far higher risk (extra 40 myocarditis events per million in 28 days)Conclusion:: mRNA vaccine myocarditis is real but rare, and far lower than myocarditis following infection. Limitations:: Observational SCCS; short follow-up window; administrative data. ME/CFS Relevance:: Harm — quantifies the vaccine-safety context (myocarditis) relevant to PVS/chronic-sequelae discussion. Certainty Assessment::
- *Quality:* High (large national SCCS)
- *Sample:* ~38M vaccinated
- *Replication:* Multiple
- *Score:* 0.75 (raw; population 0.75 → discounted 0.56)